Assessing the effect of darbepoetin alfa on patient-reported fatigue in chemotherapy-induced anemia in four randomized, placebo-controlled clinical trials
Dennis A. Revicki(United BioSource Corporation (United Kingdom)), Hema N. Viswanathan(Amgen (United States)), Margaret Vernon(United BioSource Corporation (United Kingdom)), Donald E. Stull(IQVIA (United States)), Dianne Tomita, Michael Rader(Nyack Hospital)
Cited by 8
Related Papers
The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008
|Journal of Clinical Epidemiology|2010|5.1k
ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research
|Quality of Life Research|2013|855
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
|European Journal of Cancer|2012|588
Recommendations on health-related quality of life research to support labeling and promotional claims in the United States
|Quality of Life Research|2000|575
Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy
|European Journal of Cancer|1993|545